Business Context and Reporting Period
Company: RF Acquisition Corp III (RFAM)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter ended June 30, 2026
Business Overview: RF Acquisition Corp III is a Cayman Islands exempted company formed as a blank check company (SPAC) to effect a business combination with one or more businesses, focusing on the deep technology sector in Asia (AI, quantum computing, biotechnology). The Company consummated its Initial Public Offering (IPO) on February 17, 2026, and has not yet commenced operations other than organizational activities and the search for a target.
Key Financial Metrics
| Metric | Value (as of/for period ended June 30, 2026) |
|---|---|
| Cash (Operating) | $891,600 |
| Cash Held in Trust Account | $101,273,496 |
| Total Assets | $102,219,044 |
| Net Income (3 Months) | $566,737 |
| Net Income (9 Months) | $1,239,770 |
| General & Administrative Costs (9 Months) | $455,726 |
| Interest Income (Trust Account, 9 Months) | $1,273,496 |
| Total Liabilities | $349,808 |
| Shares Outstanding (Public) | 10,000,000 (Subject to redemption) |
| Shares Outstanding (Non-Redeemable) | 3,933,333 |
Material Changes vs. Prior Period
- Trust Account Funding: As of September 30, 2025, the Trust Account balance was $0. Following the IPO on February 17, 2026, $100,000,000 was deposited, growing to $101,273,496 by June 30, 2026 due to interest earnings.
- Revenue Generation: The Company had no operating revenue in the prior period. Current period income is derived entirely from interest earned on the Trust Account and a non-cash gain from the forfeiture of the over-allotment liability.
- Over-Allotment Forfeiture: On February 19, 2026, underwriters elected not to exercise the over-allotment option. This resulted in the forfeiture of 500,000 Founder Shares and a recognized gain of $422,000 from the derecognition of the over-allotment liability.
- Equity Structure: The Company issued 10,000,000 Public Units and 350,000 Private Placement Units during the period, significantly increasing shareholders' equity compared to the inception date.
Outlook, Management Commentary, and Risks
Business Combination Agreement
On July 9, 2026 (subsequent to the reporting period), the Company entered into a Business Combination Agreement with HCC Healthcare Pte. Ltd. The transaction involves a recapitalization of HCC Healthcare to a $500 million equity value, followed by a merger. Closing is subject to shareholder approval, regulatory filings (Form F-4), and other customary conditions.
Liquidity and Capital Resources
The Company has sufficient working capital ($891,600) to operate for at least one year. The Sponsor has agreed to provide working capital loans if necessary, up to $1,500,000, which may be convertible into units upon a business combination.
Risks and Contingencies
- Combination Deadline: The Company has 21 months from the IPO closing (February 17, 2026) to complete a business combination. Failure to do so will result in liquidation and redemption of public shares.
- Geopolitical Risks: Management notes potential adverse impacts from the Russia-Ukraine and Israel-Hamas conflicts on global markets and the ability to consummate a transaction.
- Redemption Risk: Public shareholders may redeem shares for a pro-rata portion of the Trust Account, potentially reducing funds available for the business combination.
Investor Verification Checklist
- Verify the status of the Business Combination Agreement with HCC Healthcare and the timeline for shareholder approval.
- Confirm the current balance of the Trust Account and the interest rate environment affecting future accruals.
- Review the terms of the Sponsor's indemnity regarding third-party claims against the Trust Account.
- Assess the potential dilution impact of the 350,000 Private Placement Units and any future working capital loans.
- Monitor the 21-month deadline for completing a business combination to avoid forced liquidation.